摘要
采用聚合酶链反应 单链构像多态性分析 (PCR SSCP)检测结核分枝杆菌耐药基因 (rPOB、katG和rPSL) ,评估它的临床应用价值。通过Bactec 96 0快速培养、PCR SSCP和药物敏感试验了解 12 3例肺结核病人结核分枝杆菌耐药情况 ,分析了临床治疗效果。近1/ 3的初治肺结核病人至少耐一种抗结核药物 ,RFP、INH和SM敏感株rPOB、katG和rPSL基因突变率分别为 6 2 %、10 8%和 2 5 4 % ,耐药株基因突变率分别为 6 0 2 %、4 8 0 %和 6 1 5 % ,耐药基因突变率随着耐药浓度增高而增高。药敏试验联合耐药基因检测指导治疗效果满意。耐药基因检测指导治疗是一种新探索 ,与药敏试验联合应用可互相弥补 ,有可能成为临床指导用药的较好方法。
To evaluate the clinical value of PCR SSCP to detect the rPOB, katG and rPSL resistance genes in M. tuberculosis, the mutation of genes and results of drug sensitive test in strains of M. tuberculosis isolated from 123 patients and grown with Bactec 960 were analyzed, drug sensitive test and polymerase chain reaction single stranded conformation polymorphism (PCR SSCP) were performed. Clinical therapeutic effect was evaluated. In nearly one third of the patients, resistance against one drug was found in primary treatmnent. The mutation rate of RFP, INH and SM drug sensitive isolates was 6 2%, 10 8%, and 25 4%, respectively, while that of drug resistant isolates was 60 2%, 48 0%, and 61 5%, respectively. The magnitude of drug resistance was in accordance with the increase in mutation rate of genes. Detection of the resistance genes could be a new approach in guiding treatment, and it might complement drug sensitive test in clinical management of tuberculosis patients.
出处
《解放军医学杂志》
CAS
CSCD
北大核心
2002年第3期228-230,共3页
Medical Journal of Chinese People's Liberation Army
基金
全军医学科研"十五"计划面上项目 (编号 0 1MA2 1 7)
